Finding new clues to muscle damage in FSHD

Facioscapulohumeral muscular dystrophy (FSHD) causes muscles to become weaker over time, but it affects everyone differently. Some people lose strength slowly, while others experience faster progression. Even within the same muscle, some areas can be badly affected while nearby muscle remains healthy. We currently do not understand why this happens. 

Researchers have found that people with FSHD have unusually low levels of a natural protein called myostatin that normally helps control muscle growth and repair. However, we don’t know whether this change is helping muscles cope with damage or whether it’s a sign that muscles are becoming unhealthy. 

Answering this question is important because myostatin is already being studied as a way of monitoring the condition and as a possible target for new treatments. Before these approaches can be used confidently, we need to understand what changes in this protein really mean and how they relate to muscle damage in FSHD. 

This project will investigate why muscles are damaged in some parts of the body but not others in FSHD. 

This study will look at how muscles respond to two common types of stress: increased physical strain and changes in metabolism, both of which affect how muscles use and produce energy. The research team will examine whether these different types of stress change the levels of an important muscle protein called myostatin and whether these changes are linked to muscle damage, scarring or healthy repair. 

By comparing muscles at different stages of the condition, it will hopefully be clear whether changes in myostatin levels help protect muscles in the early stages or instead signal that muscles are becoming permanently damaged. 

This knowledge will help us better understand how FSHD develops and why it progresses differently from person to person.

People living with FSHD often experience very different rates of condition progression, but doctors cannot yet explain why. Understanding what happens inside muscles as the condition develops is an important step towards improving treatment. 

This research will help us understand whether an important muscle protein, myostatin, can be used to monitor progression of the FSHD and whether it could be a useful target for future treatments. By learning more about why some muscles become damaged while others remain healthy, the design of future clinical trials will hopefully be improved and the development of more effective therapies for people living with FSHD will be supported.